Vision loss rarely begins in a hospital. The problems escalate—the blurry vision, frustration, delayed healthcare, and potentially life-altering complications such as blindness in a matter that could have been treated easily if only people had sought medical assistance when they should have done it.
Yet this trend of delayed patient presentation can be considered normative in many regions of the world due to a combination of access issues and alternative healing practices.
As a young optometrist, Dr. Ebenezer Owusu watched it happen again and again.
According to Owusu, in many cases, people tend to wait until their condition has developed considerably before seeking any help: “This means that, by the time the patient seeks any help, the infection is hard to contain. I found out that most of what happens there could actually have been prevented; however, they come with conditions that are already well-established. Those experiences forced me to think beyond immediate treatment and consider what more effective, accessible solutions could look like. It became clear that clinical care alone was not enough.”
The consequences are measurable. Infectious eye disease continues to place a growing burden on healthcare systems globally, including in the United States, where hundreds of thousands of cases require urgent intervention each year.
Owusu discovered this particular problem while working in rural Ghana. The experience made him interested in translational research focused on developing therapies for early, effective treatment of multiple health problems.
What Rural Practice Revealed About Preventable Blindness
During his early professional practice, Owusu worked as a doctor in rural Ghana, a region with no high-quality medical facilities. Eye care competes with tradition, cost, and access. Patients improvised with herbal concoctions and advice from neighbors. Anything before a real doctor.
Clinical skill alone couldn’t fix this. He treated conditions that had already gone too far. Desperate patients wanted miracles.
Owusu explains: “Many patients expected immediate restoration of vision, even when the disease had progressed significantly. A key part of the clinical process involved resetting those expectations through clear communication. It required explaining how the condition developed, what treatment could realistically achieve, and why recovery often takes time. That level of understanding directly influences adherence and outcomes.”
Not all outcomes followed that trajectory.
Over the following years, he provided free examinations to 10,000 Ghanaians. One case remains unforgettable—a schoolboy struggling academically because of myopia. A simple pair of glasses changed everything. He came back later with top grades.
Owusu says: “After seeing a patient through the full course of treatment for an ocular condition, there is great excitement because everything that was hoped for happens. The patient can see again, and for the clinician, it is a very fulfilling moment. Those moments remind you why this work matters.”
From Treating Disease to Understanding It
The numerous instances of easily prevented blindness convinced Owusu that small steps were not enough.
For that reason, he enrolled in the PhD program in Physiological Optics and Vision Science at the University of Houston, where he is currently completing his dissertation (expected graduation July 2026). The shift is decisive—from treating individual cases to understanding the biology that could change treatment entirely.
In the lab, the questions got sharper.
Why do certain pathogens show resistance to commonly used medications? How do you regulate inflammation while minimizing adverse health effects? What would a truly good treatment look like?
“I reached out to professors in the United States and applied for the PhD program at the University of Houston,” Owusu says. “My goal was clear – to help our people and find effective ways of treating infections that had no good answers in the clinic.”
One line of investigation focused on an unconventional biological source: Maggots!
Maggot-Derived Therapies: An Unconventional Breakthrough
It sounds strange. But medicinal maggots have a real history in wound care. Their secretions clean infected tissue and promote its healing.
Owusu’s research takes that idea and applies it to the eye, one of the body’s most delicate surfaces.
He works with Lucilia Sericata. This insect secretes substances rich in active compounds. They are processed and sterilized to produce a substance that eliminates bacteria, reduces inflammation, and promotes tissue regeneration.
Owusu comments on this: “The idea lies in the utilization of a biological system with healing capabilities, which we isolate in order to ensure their safety and efficiency. Create a formulation that delivers antibacterial, anti-inflammatory, and regenerative effects simultaneously. This type of multi-functional therapy addresses several limitations seen in current treatment models.”
Current treatment approaches present a key limitation: Eye infections often need multiple drugs, antibiotics for bacteria, and steroids for inflammation. Other drops for healing. Steroids can raise eye pressure but cause cataracts.
Owusu wants one drop that does it all.
He says: “The main idea is to produce a product capable of eliminating pathogens, reducing inflammation, and stimulating recovery of the tissues in question. If we are able to develop something like this, that would be a huge step in the treatment of these kinds of diseases.”
As for his lab results, Owusu’s work demonstrates antibacterial activity against Pseudomonas aeruginosa, the cause of many cases of corneal infection.
His findings were supported by several peer-reviewed journals: Neotropical Entomology, Wound Repair and Regeneration, Contact Lens and Anterior Eye.
Owusu’s findings are creating a basis for the increasingly important part of emerging research into therapy.
A Global Challenge in Infectious Eye Disease
While the science begins in the laboratory, its urgency is driven by a growing public health crisis that extends far beyond Ghana.
According to CDC data, about 930,000 outpatient visits for infectious keratitis occur each year in the US. Another 58,000 ER visits. The direct costs are $175 million annually.
Then, there’s antibiotic resistance.
Studies show 30–40% resistance rates for certain eye pathogens in US clinical settings, including Pseudomonas aeruginosa. Existing drugs are losing effectiveness. The need for alternatives is urgent.
Owusu puts it bluntly: “Antibiotic resistance is a critical and escalating global health concern in ophthalmology. Traditional therapies often fail as pathogens become resistant, and the inflammation they trigger causes most of the vision loss through corneal opacities. That is the gap we are trying to close.”
His research offers a biologically derived solution that could bypass conventional resistance with fewer drugs and less risk.
Nevertheless, the impact of infectious keratitis on the U.S. healthcare system extends beyond just numbers. The condition usually requires intensive treatment protocols involving several drugs, subsequent visits, and surgery in serious cases. Consequently, it puts pressure not only on clinics and their staff but also on budgets, particularly amid increasing resistance to antibiotics.
For physicians, it is imperative not only to fight infections but also to suppress inflammatory processes and maintain corneal health.
Modern methods include a combination of antibiotic therapy and anti-inflammatory measures, which each have drawbacks and side effects. In addition, it emphasizes patient compliance, a critical factor affecting the outcome.
In turn, the project proposed by Owusu aims to minimize treatment costs without compromising efficacy. Consolidating several therapeutic components into a single drug can be part of a wider trend in U.S. healthcare aimed at increasing efficiency and clinical accuracy.
From Discovery to Clinical Application
Moving from experimental results to practical implementation is a complex process that requires knowledge of regulatory procedures, technological capabilities, and clinical requirements.
It is precisely such a perspective that Owusu gained when he completed internships in Clinical Research and Development in 2024 and Microbiology in 2025.
These roles placed him within multidisciplinary teams responsible for advancing ophthalmic products from early-stage concepts toward clinical application.
Owusu elaborates: “Working in such an environment really showed me that good science isn’t enough. The treatment should be safe, comply with regulations, and scale up for manufacturing. Each step affects the others, and the small decisions you make at the beginning might determine whether your product eventually hits the market. The experience changed my perception of doing science, putting more focus on feasibility and applicability from the get-go.”
The experience provided a new perspective on his academic endeavors, showing him the importance of developing treatments that are viable for use in a real-world setting.
Recognition and Influence in Vision Science
Recognition came swiftly. Owusu is one of the very few to receive the William C. Ezell Fellowship in consecutive years, 2024 and 2025.
The 2025 award he received was designated as the prestigious Centennial Ezell Fellowship- so named in 2022. He also received the Joe and Janet Barr Early Career Cornea and Contact Lens Research Award, the Minnie and Roseanna Turner Fund for Impaired Vision Research, and a spot in the ARVO Science Communication Training Fellowship (only 20 people selected each year globally).
Media organizations such as 3News, Citinewsroom, and the University of Houston have highlighted his achievements.
According to Dr. William Ngo, assistant professor at the University of Waterloo School of Optometry and Vision Science, who has been monitoring Owusu’s contributions to the field for some time now, says: “Dr. Owusu has maintained a consistent peer-reviewed publication record since 2020, including a high number of first-author papers published in one calendar year.
That level of productivity, combined with the originality of his work, positions him among emerging leaders in vision science and toward becoming a leading figure in the field. The repeated awarding of the Ezell Fellowship reflects a rigorous peer evaluation of both his current contributions and future potential.”
He continues: “Editors across several journals have relied on his judgment for manuscript evaluation at a volume well above the norm for researchers at this stage. That demand signals recognition of his analytical rigor and his role in shaping the direction of research within the field.”
The development of Owusu’s mini-review on maggot-derived excretions and secretions for ocular applications was published in the respected academic journal Contact Lens and Anterior Eye. It marks his initial effort to develop and implement a therapy known in wound care to ophthalmic conditions, as well as his research into epidemiology in dry eye disease.
His publications on dry eye and meibomian gland dysfunction have been cited in several globally recognized, evidence-based consensus reports from the Tear Film & Ocular Surface Society (TFOS).
These reports aim to diagnose, classify, and manage ocular surface diseases.
Specifically, his work is cited in: TFOS DEWS III: Management and Therapy; TFOS DEWS III: Digest; TFOS Lifestyle: Impact of lifestyle challenges on the ocular surface; and TFOS Lifestyle: Impact of societal challenges on the ocular surface.
In fact, his involvement in the process is even greater, as he conducted an extensive peer review of 14 papers across 9 journals in a single year.
The specific significance of his work is evident in Owusu’s focus on developing a single, multifunctional therapeutic agent. Such an approach eliminates traditional multiple-drug treatment schemes in favor of a comprehensive approach targeting all major aspects of treatment simultaneously.
This could prove highly influential for both future research in this area and actual practices.
Besides research, Owusu remains involved in other academic activities.
Since 2021, he’s been a Graduate Teaching Assistant at the University of Houston, supporting the training of future eye care professionals in slit lamp exams and refraction.
Owusu has lobbied for the cause of research into the problem of vision problems in Washington, D.C., as part of ARVO Advocacy Day.
According to Owusu: “The drive goes beyond personal success. It entails the creation of a system of collective effort and advancement. Knowledge and information are freely exchanged, the field of interest is widened, and opportunities arise for future researchers.”
Mentorship runs through his work. Africa STEM Network. Ghana’s A-Zone Network. He helps students at different stages find their way.
These efforts extend beyond individual guidance into broader capacity-building within underrepresented research communities.
As part of networks such as Africa STEM and Ghana’s A-Zone, Owusu helps shape the careers of budding researchers who might not have access to such guidance and scientific mentorship.
Additionally, his participation in advocacy efforts in Washington, D.C. demonstrates engagement at the policy-making level, which directly affects how quickly innovations can occur in vision science.
Dr. William Ngo observes: “Owusu’s exploration of maggot-based treatment methods presents a novel approach with great scientific value and promise. His research has shown that these biologic molecules are effective when used under conditions resembling those on the surface of the human eye. This body of work represents a solid foundation for developing new treatments aimed at eliminating infection and inflammation.”
Ngo also points to the broader epidemiological work: “His population-based study on dry eye disease addresses a notable gap in global data, particularly within sub-Saharan Africa. Its inclusion in international guideline reports reflects the degree to which his research informs clinical understanding on a global scale.”
A Career Guided by the Clinical Problem and Scientific Progress
From the rural setting of clinical practice to the cutting-edge realm of scientific research, each step is guided not only by career advancement but also by the importance of clinical experience in determining scientific directions.
Every phase of Owusu’s career has been motivated by the same core issue: delay, lack of treatment options, and unnecessary blindness.
As Owusu puts it: “The drive comes from tackling practical significance. Eye diseases influence learning, productivity, and general well-being, especially in disadvantaged communities. The ultimate aim is to create interventions that are not only functional but also affordable. The purpose is not just to make scientific progress but to make sure that this progress has practical implications.”
That focus continues to guide his work, positioning it at the intersection of clinical need, scientific innovation, and global health relevance.
